Listed

Atrium Therapeutics, Inc.

RNANasdaqCIK 2093101HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$3.0m, Q2 FY2026
Operating income−$22.6m, Q2 FY2026
Net income−$20.2m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m1.6Revenue, period not labelled, three months to 2025-03-31$1.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure3.8Revenue, period not labelled, three months to 2025-06-30$3.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure19.6Revenue, Q1 FY2026, three months to 2026-03-31$19.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure3.0Revenue, Q2 FY2026, three months to 2026-06-30$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Research and development$m6.9Research and development, period not labelled, three months to 2025-03-31$6.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure13.3Research and development, period not labelled, three months to 2025-06-30$13.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure16.7Research and development, Q1 FY2026, three months to 2026-03-31$16.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure15.3Research and development, Q2 FY2026, three months to 2026-06-30$15.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Operating income$m(7.5)Operating income, period not labelled, three months to 2025-03-31−$7.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(12.9)Operating income, period not labelled, three months to 2025-06-30−$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(17.3)Operating income, Q1 FY2026, three months to 2026-03-31−$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(22.6)Operating income, Q2 FY2026, three months to 2026-06-30−$22.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Net income$m(7.4)Net income, period not labelled, three months to 2025-03-31−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(12.9)Net income, period not labelled, three months to 2025-06-30−$12.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(16.6)Net income, Q1 FY2026, three months to 2026-03-31−$16.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(20.2)Net income, Q2 FY2026, three months to 2026-06-30−$20.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Diluted EPS$ per share(0.44)Diluted EPS, period not labelled, three months to 2025-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(0.75)Diluted EPS, period not labelled, three months to 2025-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(0.97)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(1.18)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Basic EPS$ per share(0.44)Basic EPS, period not labelled, three months to 2025-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(0.75)Basic EPS, period not labelled, three months to 2025-06-30−$0.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(0.97)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.97 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(1.18)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure

Balance sheet

Cash and equivalents$72.3m, Q2 FY2026
Shareholders' equity$214.6m, Q2 FY2026
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31period not labelled2026-02-26Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported0.0Cash and equivalents, period not labelled, at 2025-03-31$0. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure0.0Cash and equivalents, period not labelled, at 2025-06-30$0. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure0.0Cash and equivalents, period not labelled, at 2025-12-31$0. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure270Cash and equivalents, period not labelled, at 2026-02-26$270.0m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure268Cash and equivalents, Q1 FY2026, at 2026-03-31$267.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure72.3Cash and equivalents, Q2 FY2026, at 2026-06-30$72.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Current assets$mnot reportednot reportednot reported2.8Current assets, period not labelled, at 2025-12-31$2.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figurenot reported286Current assets, Q1 FY2026, at 2026-03-31$285.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure275Current assets, Q2 FY2026, at 2026-06-30$275.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Total assets$mnot reportednot reportednot reported8.4Total assets, period not labelled, at 2025-12-31$8.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figurenot reported292Total assets, Q1 FY2026, at 2026-03-31$292.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure281Total assets, Q2 FY2026, at 2026-06-30$280.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Current liabilities$mnot reportednot reportednot reported41.8Current liabilities, period not labelled, at 2025-12-31$41.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figurenot reported21.9Current liabilities, Q1 FY2026, at 2026-03-31$21.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure31.5Current liabilities, Q2 FY2026, at 2026-06-30$31.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Total liabilities$mnot reportednot reportednot reported71.1Total liabilities, period not labelled, at 2025-12-31$71.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figurenot reported58.3Total liabilities, Q1 FY2026, at 2026-03-31$58.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure65.9Total liabilities, Q2 FY2026, at 2026-06-30$65.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure
Shareholders' equity$m(61.1)Shareholders' equity, period not labelled, at 2024-12-31−$61.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(56.3)Shareholders' equity, period not labelled, at 2025-03-31−$56.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(56.2)Shareholders' equity, period not labelled, at 2025-06-30−$56.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure(62.7)Shareholders' equity, period not labelled, at 2025-12-31−$62.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figurenot reported234Shareholders' equity, Q1 FY2026, at 2026-03-31$234.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure215Shareholders' equity, Q2 FY2026, at 2026-06-30$214.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure

Cash flow

Operating cash flow−$3.9m, Q2 FY2026
Capital expenditure$36.0k, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(11.1)Operating cash flow, period not labelled, three months to 2025-03-31−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(11.9)Operating cash flow, period not labelled, three months to 2025-06-30−$11.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349488. Derived: 6-month figure less the 3-month figure.Report this figure(31.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$31.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure(3.9)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349488. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, period not labelled, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure0.3Capital expenditure, period not labelled, three months to 2025-06-30$266.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349488. Derived: 6-month figure less the 3-month figure.Report this figure2.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$36.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349488. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)17.11m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares17.1Diluted shares (weighted), period not labelled, three months to 2025-03-3117,105,643 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure17.1Diluted shares (weighted), period not labelled, three months to 2025-06-3017,106,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure17.1Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3117,105,643 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224243.Report this figure17.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3017,106,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure

Shares outstanding: 17.11mShares outstanding, period not labelled, at 2026-08-0317,105,643 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349488.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.